Introduction to AR Animal Models

Animal models of allergic rhinitis (AR) are predominantly established using mice and rats, often employing a protocol that combines ovalbumin with an adjuvant for sensitization and challenge. This approach induces in the animals hallmark symptoms such as nasal pruritus, sneezing, clear rhinorrhea, nasal mucosal edema, and inflammatory cell infiltration, thereby mimicking the clinical features of human allergic rhinitis. These models are valuable for investigating the underlying immunological mechanisms, airway inflammation, and the development of novel therapeutics.

Advantages of Aniphe BioLab’s AR Animal Model Platform Services

This platform boasts a standardized animal model for allergic rhinitis (AR), complete with a robust construction and evaluation system. With rigorous quality control and reliable delivery, it fully meets the needs of both research studies and new drug development.

	Classic modeling system Using an ovalbumin–adjuvant sensitization–challenge protocol, the animals exhibit typical rhinitis symptoms, closely mimicking the clinical disease phenotype.
	The model exhibits strong stability. Behavioral performance, inflammatory markers, and immune-related indicators are well‑balanced and consistent, with a high modeling success rate and excellent experimental reproducibility.
	Multi-dimensional detection capability It encompasses a comprehensive suite of evaluation parameters, including behavioral scoring, nasal mucosal pathology, inflammatory cytokines, and immune markers.
	The experimental protocol is flexible. The sensitizing concentration, stimulation frequency, and observation period can be adjusted as needed to suit different research objectives.
	Closed-loop one-stop service The entire workflow—from model generation and animal care to sample analysis—is performed autonomously, efficiently supporting both basic research and IND submissions.

Modeling cycle	4–6 weeks
Laboratory animals	SPF-grade rats
Positive drug	Commonly used positive control medications, such as loratadine and mometasone furoate, can effectively alleviate symptoms like nasal pruritus, sneezing, and rhinorrhea, while suppressing local allergic and inflammatory responses.
Application areas	This model is primarily used to investigate the allergic immune mechanisms underlying allergic rhinitis and the patterns of inflammatory injury in the nasal mucosa. It also facilitates the screening of pharmacological efficacy and the assessment of safety for anti-allergic, anti-inflammatory, and intranasal formulations. Furthermore, it can be employed for validating drug targets and advancing innovative drug development, thereby supporting both basic research and preclinical programs such as IND submissions.

AR Animal Model Construction

Ovalbumin (OVA) is used as the sensitizing antigen, and the model is established in two steps: systemic sensitization followed by local intranasal challenge. First, OVA combined with an adjuvant is administered via intraperitoneal injection to induce systemic active sensitization, thereby activating the host’s allergic immune response. Subsequently, a daily intranasal instillation of OVA solution serves as a local challenge, continuously stimulating the nasal mucosa. Over time, the animals develop typical rhinitis symptoms, including sneezing, nose scratching, clear rhinorrhea, and nasal mucosal congestion and edema, reliably mimicking the pathological and clinical features of human allergic rhinitis. This approach is currently the most widely employed method for establishing an AR animal model.

Model features: In studies of allergic rhinitis, animal models exhibit symptoms such as sneezing, nasal scratching, facial rubbing, and nasal discharge, with a pronounced late-phase response. The rat model combines the advantages of both guinea pig and mouse models, offering convenient administration and appropriate sample volumes.